Roivant Sciences Ltd (FRA:87S)
€ 10.975 -1.02 (-8.5%) Market Cap: 8.42 Bil Enterprise Value: 3.37 Bil PE Ratio: 2.16 PB Ratio: 1.74 GF Score: 60/100

Roivant Sciences Ltd at Guggenheim Healthcare Talks Biotechnology Conference Transcript

Feb 07, 2024 / 07:30PM GMT
Release Date Price: €9.2 (+2.79%)
Yatin Suneja
Guggenheim Securities, LLC, Research Division - Senior MD & Equity Research Analyst

Okay. Good afternoon, everyone. Yatin Suneja from Guggenheim. Welcome to our 6th Annual Biotechnology Conference. Our next presenting company is Roivant. From the company, we have Chief Financial Officer Richard Pulik. Richard, why don't you give maybe a 5-minute overview of the company, maybe talk about some of the upcoming milestones, and then we'll go into the Q&A.

Richard Pulik
Roivant Sciences Ltd. - CFO

Great. Thanks so much for having us, Yatin, and for your great coverage. Look, I think it's a super exciting year for us. We have, post the Telavant deal, roughly $7 billion in cash, which makes us one of the best capitalized biotech companies out there. I think that drives a lot of optionality to do more deals. We're -- obviously, in our 10-year history, have done some pretty spectacular deals and are continuing to remain very active there.

I would say, on the back of JPMorgan, it was probably one of the most exciting years I've seen. Lots

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot